



Certificate of Approval of a Prospectus
pursuant to Sections 17 and 18 German Securities Prospectus Act
transposing Articles 17 and 18 of Directive 2003/71/EC

To:

Autorité des marchés financiers (AMF), France
Finanstilsynet (Danish FSA), Denmark
The Financial Conduct Authority (FCA), United Kingdom (UK)

From:

Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin)
Federal Financial Supervisory Authority, Germany

We hereby certify that the Prospectus detailed below has been drawn up in accordance with the German Securities Prospectus Act transposing Directive 2003/71/EC and was approved by us on 29.03.2016.

Name of Issuer:

Biogen Inc.

Registered Office/Seat:

United States, Cambridge, 225 Binney Street

Type of Security :

Employee Stock Purchase Plan (Mitarbeiterbeteiligungsprogramm) / WKN: 789617 /
ISIN: US09062X1037 (relating to DK, FR, GB)

References to the annexes of Regulation EC 809/2004 according to which the prospectus was drawn up: Annex I, Annex III, Annex XXII

Guarantor (if any): n.a.

Yours faithfully,



(Pfeil)

This CoA is valid without signature

Prospectus Group, Section WA 52
Federal Financial Supervisory Authority
Securities Supervision / Asset Management
Date: 29.03.2016
Reference: WA 52-Wp 7107-40008347-2016/0001

Attachments:

(1) Prospectus dated 24.03.2016